The company said the quarter’s sales growth played out as expected, “other than one dynamic with respect to the timing of the respiratory season.” For the full year, the company continues to expect a normal sized flu season, but does see a timing shift which translates to the movement of approximately $30M of flu testing revenue from fiscal Q1 to the remainder of the year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BDX:
- Accelerate Diagnostics price target lowered to $2 from $5 at Craig-Hallum
- Becton Dickinson to pay $85M in infusion pump settlement
- Becton Dickinson granted exclusive license by Bactiguard for Foley catheters
- Becton Dickinson price target lowered to $280 from $310 at Morgan Stanley
- Becton Dickinson reports FDA safety communication doesn’t impact BD syringes
